fbpx
  • Topics
    • AI & Big Data
    • AR & VR
    • Blockchain
    • Clean Technology
    • Content & Games
    • Cybersecurity
    • Enterprise & SaaS
    • Gadgets & Electronics
    • Health & Bio
    • FinTech
    • IoT
    • Transportation & Logistics
    • Marketplaces & E-commerce
    • Ecosystem
    • Robotics
    • Investments
    • EdTech
    • Featured
  • Deals
    • Private Equity
    • Venture Capital
    • IPO & Markets
  • Interviews
    • Startup Investing
    • Fundraising
    • Product Launching
  • MORE
    • Events
    • Startups Advice
  • Submit an Article
  • REGISTER
  • login
No Result
View All Result
No Result
View All Result
Home Private Equity

Hong Kong PE Firm PAG Pays $540m for Majority Stake in Hisun BioRay

AsiaTechDaily Writer by AsiaTechDaily Writer
05 September 2019
in Private Equity
0
PAG Hisun BioRay
67
SHARES
Share on FacebookShare on Twitter
Bookmark (0)

Please login to bookmark

No account yet? Register

Hong Kong-headquartered private equity firm PAG is paying about Rmb3.8 billion (US$540 million) for a controlling stake in Chinese biopharma company Hisun BioRay, according to a company statement.

The Asia-focused PAG will acquire 58 percent in Hisun BioRay, the R&D and manufacturing platform of Shanghai-listed pharmaceutical giant Zhejiang Hisun Pharmaceutical, in what is considered as one of the biggest deals in the country’s biotechnology industry so far.

Hisun Pharmaceutical will continue to retain 42 percent ownership of the company while Xiao Suining, partner and chairman of PAG China, will come in as the new chairman of Hisun BioRay.

Established in January 2019, Hisun BioRay serves as the core business division of Hisun Pharmaceutical. With two R&D and manufacturing centers in Taizhou and Hangzhou, the firm also serves as platform for R&D, manufacturing, sales of Hisun’s biologic anti-body based drugs.

In a statement, Hisun BioRay said it has developed a strong portfolio in the auto-immune and oncology treatment areas. It manufactures and markets Anbainuo®, a leading biosimilar drug indicated for auto-immune disorder including rheumatoid arthritis, ankylosing spondylitis, and psoriasis.

Before the end of this year, the pharma firm, which has more than 700 employees, plans to launch Anjianning®, one of China’s first adalimumab biosimilars.

Hisun BioRay CEO Dr. Wang Haibin said the investment from PAG will help the pharma firm in accelerating the development of its pipeline and clinical trial progress. It will also strengthen the company’s competitive advantage and positions it further as leader in the latest generation of innovative biologics and biosimilars.

For Kevin Xu, head of PAG Growth Capital, the investment in Hisun BioRay further underscores PAG’s strong commitment to China’s biotech industry. The private equity firm recently invested in other biotech firms in China, including Alphamab Oncology and Rongchant Pharmaceuticals.

Hisun Pharmaceutical, the seller of the stake, is listed on the Shanghai Stock Exchange and is headquartered in Taizhou, Zhejiang province.

Tags: BiopharmaHisun BioRayPAGPrivate Equity
Previous Post

Korea’s Hanwha Investing US$4m in Capital Raising Platform CapBridge

Next Post

Leben Care, Singapore- An AI Based Ophthalmology Platform

Related Posts

edit post
Profet AI
Private Equity

BPEA makes final close of largest private fund at $475m

November 1, 2022
edit post
Fullerton
Private Equity

Asian investment specialist Fullerton raises $100m first close for Thai PE strategy

May 31, 2022
edit post
Teazen
Featured

VIG Partners to acquire Korean tea-based drinks firm Teazen

April 26, 2022
edit post
ResultsCX
Featured

ChrysCapital acquires customer experience firm ResultsCX

October 5, 2021
edit post
KT Corp
Featured

South Korea’s KT Corp acquires Singapore-headquartered Epsilon Telecommunications

September 10, 2021
edit post
Circles.Life
Private Equity

Singapore Telco Circles.Life Eyes Expansion After Warburg Pincus Investment

February 12, 2020
Next Post
edit post
Leben Care

Leben Care, Singapore- An AI Based Ophthalmology Platform

Discussion about this post

No Result
View All Result

Follow Us

FREE NEWSLETTER




Copyright © 2023 AsiaTechDaily.com| About Us | Seed accelerator| Terms of Use| Privacy Policy| Cookie Policy Contact : [email protected] | DMCA.com Protection Status | trusted by Wimgo

No Result
View All Result
  • Topics
    • AI & Big Data
    • AR & VR
    • Blockchain
    • Clean Technology
    • Content & Games
    • Cybersecurity
    • Enterprise & SaaS
    • Gadgets & Electronics
    • Health & Bio
    • FinTech
    • IoT
    • Transportation & Logistics
    • Ecosystem
    • Marketplaces & E-commerce
    • Robotics
    • Investments
    • Featured
  • Deals
    • Private Equity
    • Venture Capital
    • IPO & Markets
  • Interviews
    • Startup Investing
    • Fundraising
    • Product Launching
  • MORE
    • Events
    • Startups Advice
  • Submit an Article
  • Forums
  • Jobs
  • REGISTER
  • Login

Copyright © 2023 AsiaTechDaily.com| About Us | Seed accelerator| Terms of Use| Privacy Policy| Cookie Policy Contact : [email protected] | DMCA.com Protection Status | trusted by Wimgo

We hope you enjoy our content, May you please give us Feedback regarding our website!

Single Post Feedback